Bain Capital Investors LLC Cerevel Therapeutics Holdings, Inc. Transaction History
Bain Capital Investors LLC
- $4.48 Billion
- Q1 2024
A detailed history of Bain Capital Investors LLC transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, Bain Capital Investors LLC holds 65,679,781 shares of CERE stock, worth $2.69 Billion. This represents 61.94% of its overall portfolio holdings.
Number of Shares
65,679,781
Previous 65,679,781
-0.0%
Holding current value
$2.69 Billion
Previous $2.78 Billion
0.31%
% of portfolio
61.94%
Previous 60.39%
Shares
3 transactions
Others Institutions Holding CERE
# of Institutions
227Shares Held
150MCall Options Held
939KPut Options Held
961K-
Perceptive Advisors LLC New York, NY10.8MShares$441 Million9.58% of portfolio
-
Avoro Capital Advisors LLC New York, NY7.56MShares$309 Million3.85% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.46MShares$305 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.45MShares$223 Million0.01% of portfolio
-
State Street Corp Boston, MA3.53MShares$144 Million0.01% of portfolio
About Cerevel Therapeutics Holdings, Inc.
- Ticker CERE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 155,752,000
- Market Cap $6.37B
- Description
- Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...